Sign in
CompletedPhase 3

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Key facts

Who runs it
GlaxoSmithKline
Where
Anaheim, Baltimore, Bardstown, Beaumont, Bingham Farms, Birmingham, Boone, Bryan, Charleston, Cincinnati, Clarksville, Dayton, Edinburg, Fairfield, Fall River, Fayetteville, Hermitage, Houston, Jonesboro, Kansas City, Kingsport, Lake Mary, Layton, Lincoln, Liverpool, Louisville, Marshfield, Miami, Nampa, Newton, Oakland, Omaha, Orem, Pittsburgh, Provo, Raleigh, Richmond, Roseville, Roy, Salt Lake City, San Antonio, Sioux Falls, South Euclid, Spokane, Syracuse, Tampa, Topeka, Walnut Creek, and West Covina, United StatesSee the 49 sitesAlso in 1 other country, 1 site
Status
Completed
Phase
Phase 3
People taking part
1,196 people enrolled
Started
27 Jul 2018
Ended
27 Dec 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ)
  • Prevnar13
  • Pediarix
  • Hiberix
  • Rotarix
  • M-M-R II
  • Varivax
  • Placebo (saline water)
  • Prevnar 20
Record updated
20 August 2026

Who can take part

Age
6 weeks to 12 weeks
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • All subjects must satisfy all the following criteria at study entry:
  • Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the eDiary, return for follow-up visits)
  • Written informed consent obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure
  • A male or female between, and including, 42 and 84 days of age (i.e., 6 through 12 weeks) at the time of the 1st vaccination
  • Healthy subjects as established by medical history and clinical examination before entering into the study
  • Born full-term (i.e. after a gestation period of ≥ 38 weeks)

Who cannot take part

  • Received immunoglobulins or any blood products from birth
  • Received an investigational or non-registered medicinal product from birth
  • Current or previous, confirmed or suspected disease caused by N. meningitidis
  • Previous administration of meningococcal B or pneumococcal vaccine at any time prior to informed consent
  • Received a dose of DTPa-HBV-IPV, HRV, MMR, VV and/or Hib at any time prior to informed consent. Receipt of one dose of HBV up to 4 weeks prior to informed con-sent is allowed
  • Progressive, unstable or uncontrolled clinical conditions
  • Hypersensitivity, including allergy to any component of vaccines, medicinal product or medical equipment whose use is foreseen in this study
  • Hypersensitivity to latex
  • Clinical conditions representing a contraindication to intramuscular vaccination and blood draws
  • Abnormal function of the immune system resulting from:; Clinical conditions; Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days from birth; Administration of antineoplastic and immunomodulating agents or radiotherapy for any duration from birth; Autoimmune disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes)
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study
  • Neuroinflammatory disorders (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital and peripartum neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalised tonic-clonic seizures, partial complex seizures, partial simple seizures or febrile convulsions)
  • Congenital or peripartum disorders resulting in a chronic condition (including but not limited to: chromosomal abnormalities, cerebral palsy, metabolism or synthesis disorders, cardiac disorders)
  • Serious chronic illness
  • Household contact with and/or intimate exposure from birth to an individual with laboratory confirmed N. meningitidis and/or Streptococcus pneumoniae infection or colonization
  • If any exclusion criterion applies, the subject must not be included in the study:
  • Child in care; Each subject must not have:
  • Study personnel as an immediate family or household member
  • Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for Intussusception (IS)

Where in United States

Also in 1 other country, 1 site

  • Anaheim, CaliforniaHospital not named in the registry
  • Baltimore, MarylandHospital not named in the registry
  • Bardstown, KentuckyHospital not named in the registry
  • Beaumont, TexasHospital not named in the registry
  • Bingham Farms, MichiganHospital not named in the registry
  • Birmingham, AlabamaHospital not named in the registry
  • Boone, North CarolinaHospital not named in the registry
  • Bryan, TexasHospital not named in the registry
  • Charleston, South CarolinaHospital not named in the registry
  • Cincinnati, OhioHospital not named in the registry
  • Clarksville, TennesseeHospital not named in the registry
  • Dayton, OhioHospital not named in the registry
  • Edinburg, TexasHospital not named in the registry
  • Fairfield, OhioHospital not named in the registry
  • Fall River, MassachusettsHospital not named in the registry
  • Fayetteville, ArkansasHospital not named in the registry
  • Hermitage, TennesseeHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Jonesboro, ArkansasHospital not named in the registry
  • Kansas City, MissouriHospital not named in the registry
  • Kingsport, TennesseeHospital not named in the registry
  • Lake Mary, FloridaHospital not named in the registry
  • Layton, UtahHospital not named in the registry
  • Lincoln, NebraskaHospital not named in the registry
  • Liverpool, New YorkHospital not named in the registry
  • Louisville, KentuckyHospital not named in the registry
  • Marshfield, WisconsinHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Nampa, IdahoHospital not named in the registry
  • Newton, KansasHospital not named in the registry
  • Oakland, CaliforniaHospital not named in the registry
  • Omaha, NebraskaHospital not named in the registry
  • Orem, UtahHospital not named in the registry
  • Pittsburgh, PennsylvaniaHospital not named in the registry
  • Provo, UtahHospital not named in the registry
  • Raleigh, North CarolinaHospital not named in the registry
  • Richmond, VirginiaHospital not named in the registry
  • Roseville, CaliforniaHospital not named in the registry
  • Roy, UtahHospital not named in the registry
  • Salt Lake City, UtahHospital not named in the registry
  • San Antonio, TexasHospital not named in the registry
  • Sioux Falls, South DakotaHospital not named in the registry
  • South Euclid, OhioHospital not named in the registry
  • Spokane, WashingtonHospital not named in the registry
  • Syracuse, New YorkHospital not named in the registry
  • Tampa, FloridaHospital not named in the registry
  • Topeka, KansasHospital not named in the registry
  • Walnut Creek, CaliforniaHospital not named in the registry
  • West Covina, CaliforniaHospital not named in the registry

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccinesv(RIV).

The 2 groups in the trial

  • MenB+PCV GroupTreatment being tested

    Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301.

    Treatment: Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ), Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, and Prevnar 20

  • Placebo+PCV GroupPlacebo, for comparison

    Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301.

    Treatment: Prevnar13, Pediarix, Hiberix, Rotarix, M-M-R II, Varivax, Placebo (saline water), and Prevnar 20

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
20 August 2026